AACC uses Cookies to ensure the best website experience. Continuing without changing Cookie settings assumes you consent to our use of cookies on this device. You can change these settings at any time, but that may impair functionality on our websites. Review our cookie and privacy policy

Mass Spectrometry Topic Track

Mass spectrometry is moving from an experimental or highly specialized technology to an essential part of routine practice in laboratory medicine. Whether you expect to implement mass spectrometry in your laboratory soon, or already are an experienced user, there are sessions to choose from that fit your educational needs.


Building New or Adding On: Fundamentals for Overcoming Challenges in Operationalizing Clinical Mass Spectrometry 72106

This session aims to assist clinical laboratorians interested in implementing mass spectrometry for the first time and those wanting to expand their existing mass spectrometry operations. It will cover essential considerations and effective approaches needed to overcome common hurdles experienced when contemplating or utilizing mass spectrometry.

Moderator: Y. Victoria Zhang, University of Rochester Medical Center, Rochester, NY.

Speakers: Steps to Success in LC-MS/MS Staff Training and Competence, Shannon Haymond, PhD, DABCC, Lurie Children’s Hospital of Chicago, IL; Closing the Technology Gap to Bring LC-MS/MS to Your Clinical Lab, Deborah French, PhD, DABCC, FACB, University of California San Francisco; Build a Compelling Business Plan for the Right LC-MS/MS System for Your Lab, Y. Victoria Zhang, University of Rochester Medical Center, Rochester, NY.

Be Prepared! Sample Preparation Strategies for Multiple Matrices in the LC-MS/MS Clinical Toxicology Laboratory 72414

This session will describe the differences in composition among urine, blood, oral fluid, meconium, and umbilical cord tissue and the relevance of each specimen to drug testing. The differences in concentrations and distribution of drugs and metabolites and matrix challenges will be discussed. Methods for individual drug analytes will be presented for each specimen to demonstrate strategies and solutions for successful LC-MS/MS analyses.

Moderator: Stephanie Marin, PhD, ARUP Institute for Clinical and Experimental Pathology, Salt Lake City, UT.

Speakers: Sample Preparation Techniques for Detection of Drugs and Metabolites in Blood and Oral Fluid by LC-MS/MS, Christine Moore, PhD, DSc, DABCC, Immunalysis Corporation, Pomona, CA; Optimizing Sample Preparation for Analysis of Drug Analytes in Urine, Meconium, and Umbilical Cord Tissue Using LC-MS/MS, Stephanie Marin, PhD, ARUP Institute for Clinical and Experimental Pathology, Salt Lake City, UT.

*Brown Bag Session: An Introduction to Metabolomics for Translational and Clinical Labs 42124 (Repeats as 52224)

Speaker: Lacy Moss, BS, PhD, MLS(ASCP), Wake Forest Baptist Medical Center, Winston-Salem, NC.


The Emerging Role of Mass Spectrometry in the Measurement of Monoclonal Immunoglobulins 33104

Mass spectrometry is an emerging analytical tool for measuring monoclonal immunoglobulins with the potential to impact how monoclonal gammopathies are diagnosed and managed. This session will explore the rationale and utility of mass spectrometry-based methods in the context of current clinical assays used to detect, measure, and characterize monoclonal gammopathies.

Moderator: John Mills, PhD, Mayo Clinic, Rochester, MN.

Speakers: The Principles of M-Protein Detection: The Need for More Sensitive Serum-Based Methods, David Murray; Development and Application of Mass Spectrometry-Based Methods for Measuring M-proteins, John Mills, PhD, Mayo Clinic, Rochester, MN.

The Next Frontier in Precision Medicine—Targeted Peptide Diagnostic Mass Spectrometry Assays 33212

Developed in cooperation with the AACC Clinical Translational Science Division, AACC Mass Spectrometry and Separation Sciences Division, AACC Proteomics & Metabolomics Division, and the National Cancer Institute.

Diagnostic biomarkers are essential for the success of precision medicine and translational research. Yet, currently there are only 600 proteins for which biomarker diagnostic assays exist. Targeted mass spectrometry peptide-based assays (multiple reaction monitoring (MRM), also referred to as selected reaction monitoring) have emerged as a viable platform for biomarker assays in modern disease management. This symposia will present real-world examples that showcase this methodology, including its deployment at clinical reference labs and clinical utility in thyroid cancer. Practical instructions (methods development) on how to design and deploy mass spectrometry peptide assays in labs and develop highly validated off-the-shelf immuno-MRM assays (through a public-private partnership) will be provided. Best practices for the generation, quantification, storage, and handling of peptide reference standards will also be discussed.

Moderator: Henry Rodriguez, PhD, MBA, National Cancer Institute, Bethesda, MD; Y. Victoria Zhang, University of Rochester Medical Center, Rochester, NY.

Speakers: Using Standardized, Targeted Mass Spectrometry Assays to Harmonize Protein Quantification, Amanda Paulovich, MD, PhD, Fred Hutchinson Cancer Research Center, Seattle, WA; Clinical Laboratory Thyroglobulin (Tg) Function Test Revisited: Tg Peptide MS Assays, TgAb Assays, and Correlation of Results With Clinical Outcomes, Stefan Grebe, MD, PhD, Mayo Clinic, Rochester, MN; Development, Hardening, and Dissemination of Targeted Peptide Assays by Mass Spectrometry, Mike MacCoss, PhD, Professor of Genome Sciences, University of Washington, Seattle, WA.

*Brown Bag Session: Smart LCMS: The Key to Worry Free Method Development and Implementation 43111 (Repeats as 53211)

Speaker: Lorin Bachmann, PhD, DABCC, Virginia Commonwealth University, Richmond, VA.


Plenary Session: Direct Mass Spectrometric Profiling of Biological Tissues - A New Paradigm in Histology 14001

This lecture will discuss the use of direct mass spectrometric profiling of biological tissues. One example is the ‘intelligent knife’ technology, in which smoke collected during surgery performed using electrosurgical knives is analyzed by a mass spectrometer. This technology provides rapid diagnostic information to surgeons, such as during tumor resection. Professor Zoltan Takats is a pioneer in the field of ambient mass spectrometry and its application to clinical specimens near the surgical suite. With the invention of the intelligent knife, mass spectrometry is now being brought directly to patients undergoing surgery. As part of the session, an experienced anatomic pathologist, Dr. Virginia LiVolsi from the Perelman School of Medicine at the University of Pennsylvania, will give her view of the technology and participate in the post-lecture Q&A.

Speakers: Zoltan Takats, PhD, Imperial College London, United Kingdom; Virginia LiVolsi, MD, University of Pennsylvania, Perelman School of Medicine.

Meet the Expert: Direct Mass Spectrometric Profiling of Biological Tissues - A New Paradigm in Histology 64101

This session provides an excellent opportunity for a limited number of attendees to meet with Professor Zoltan Takats and Dr. Virginia LiVolsi. Professor Takats is a pioneer in the field of ‘Ambient Mass Spectrometry’ and is an inventor of the ‘intelligent knife’ technology. This technology provides real-time and clinically important information to surgeons during the course of surgery. Dr. LiVolsi is an experienced anatomic pathologist who will give her view of the technology.

Speakers: Zoltan Takats, PhD, Imperial College London, United Kingdom; Virginia LiVolsi, MD, University of Pennsylvania, Perelman School of Medicine.

Sampling, The Next Generation: Emerging Clinical Mass Spec Applications in Alternative Matrices 74214
Developed in cooperation with the AACC Mass Spectrometry and Separation Sciences Division.

This short course will interrogate the use of emerging alternative specimens for mass spectrometry in the clinical lab. Applications and challenges related to the use of alternative matrices such as dried blood spots, meconium, cord tissue, and luminal fluids will be discussed. Performance of conventional specimens for immunosuppressants, drugs of abuse, and therapeutic drug monitoring will be compared to these emerging alternative matrices to support research trials and clinical diagnostics.

Moderator: Kara Lynch, PhD, DABCC, University of California/San Francisco General Hospital.

Speakers: Spotting Spotty Spots: Considerations in Monitoring Immunosuppressants in Dried Blood Spots, Jane Dickerson, PhD, DABCC, University of Washington and Seattle Children's Hospital; You’re Testing in What? Antiviral Drug Measurements in Luminal Fluids To Support Clinical Trials, Mark Marzinke, PhD, DABCC, Johns Hopkins University School of Medicine, Baltimore, MD; Beyond Urine and Serum: Meconium and Umbilical Cord Tissue As Specimen Types, Steven Cotten, PhD, DABCC, Ohio State University Wexner Medical Center, Columbus.

*Brown Bag Session: Mass Spectrometry in the Clinical Lab: Applications for Emergency Toxicology 44103 (Repeats as 54203)

Speaker: Jennifer Colby, PhD, DABCC, Vanderbilt University, Nashville, TN.

*Brown Bag Session: Evaluation of Time-of-Flight High Resolution Mass Spectrometry for Broad Spectrum Drug Screening in Urine 44122 (Repeats as 54222)

Speaker: Imir Metushi, University of California San Diego - CALM, San Diego, CA.

*About Brown Bag sessions: These small discussion settings provide intimate exchanges between participants and experts. Expect lively conversation, dialogue, and debate, as well as Q&As. Attendance is limited to 10 participants. Advance registration and fees are required.